How to reconstitute AOD-9604 (and why the trial record still matters)

Last updated 2026-07-25

what is AOD-9604 and why does reconstitution even come up

AOD-9604 is a synthetic fragment of human growth hormone, specifically the 176-191 region, the piece of the hGH molecule that researchers isolated because it seemed to carry the fat-metabolizing (lipolytic) activity of full hGH without the growth-promoting effects on bone and tissue. That's the whole rationale: take the part of HGH that might burn fat, leave out the part that makes you grow. It shows up almost exclusively as a lyophilized (freeze-dried) powder in a sealed vial, which means someone has to add liquid to it before it can be drawn into a syringe. That step is reconstitution. It sounds technical but it's mechanically simple. The part people get wrong isn't the mixing, it's assuming that because the mixing works, the compound works. A 2004 review in Current Opinion in Investigational Drugs covered AOD-9604's proposed metabolic action, describing it as a fragment designed to retain the fat-reducing activity of the hGH molecule ^[1]. That's a mechanism paper, not a human outcomes trial, and the distinction matters for everything that follows.

what do you actually need to reconstitute AOD-9604

You need four things: the vial of lyophilized peptide, bacteriostatic water (not plain sterile water, and never tap or distilled water), an alcohol swab, and a syringe with a fine needle (an insulin syringe, typically 29-31 gauge, is standard). Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which is why it's preferred over plain sterile water for multi-dose vials, it slows bacterial growth across repeated draws. Sterile water without a preservative is meant for a single use and doesn't hold up over days or weeks of storage. You don't need heat, a stir plate, or any special equipment. Room temperature bacteriostatic water works fine. The core technique is the same one used for reconstituting most lyophilized peptides, not something unique to AOD-9604. A quick checklist: - Bacteriostatic water (0.9% benzyl alcohol), refrigerated after opening

• Alcohol swabs, one per puncture
• Syringe and needle, insulin-style for the actual dosing draw
• A vial of lyophilized AOD-9604 with intact seal

how do you actually reconstitute AOD-9604 step by step

Wipe the rubber stopper of the peptide vial and the bacteriostatic water vial with an alcohol swab and let them air dry for a few seconds. Don't blow on them or wipe them again, that reintroduces contamination. Draw the bacteriostatic water into your syringe. The exact volume depends on the vial's peptide content and the concentration you want, but a common approach for a 2 mg or 5 mg vial is somewhere between 1 mL and 3 mL of water, which changes the final concentration accordingly (more water means a more dilute solution and a larger injection volume per dose, less water means the opposite). Insert the needle through the stopper at an angle and let the water run down the inside wall of the vial rather than shooting it directly onto the powder. Direct force onto the lyophilized cake can denature the peptide's structure. Do not shake the vial. Ever. Shaking creates mechanical stress and foam that can break peptide bonds. Instead, roll the vial gently between your palms, or just let it sit undisturbed. Most lyophilized peptides fully dissolve within a few minutes at room temperature without any agitation at all. Once the powder is fully dissolved, the solution should look clear, with no visible particles, cloudiness, or fibers. If it looks off, don't use it.

how much bacteriostatic water should you use

There's no single right answer. It depends on your vial's total peptide content and how many micrograms you want per injection. More diluent gives you a lower concentration and finer dosing control at the cost of a larger injection volume; less diluent concentrates the dose into a smaller volume. Here's a simple reference table for common combinations. These are illustrative concentration math, not a recommendation on dose.

Once you know the concentration, an insulin syringe marked in units (where 100 units = 1 mL on a standard U-100 syringe) lets you draw a precise volume corresponding to your target microgram dose. If math isn't your thing, work it out on paper before you draw anything into the syringe, not while the needle is already in the vial.

how should reconstituted AOD-9604 be stored

After reconstitution, the vial goes in the refrigerator, not the freezer. Cold slows the degradation of the peptide bonds; freezing and thawing repeatedly can damage them just as much as shaking does. Most compounded peptide solutions are treated as stable for a matter of weeks under refrigeration once mixed, though exact stability depends on the diluent, concentration, and storage conditions, and there's no large published stability trial specific to reconstituted AOD-9604 that we can point to with a number attached. Keep the vial away from light, and don't let it sit out at room temperature for extended periods. For more detail on how long unreconstituted (lyophilized) AOD-9604 lasts on the shelf, and what shortens that window, see our AOD-9604 storage and shelf life guide.

does AOD-9604 actually work for fat loss in humans

This is the part that matters more than any reconstitution technique, and it's the part a lot of sellers skip. AOD-9604 went through human obesity trials. The weight-loss results did not separate convincingly from placebo. A 2006 review of obesity drugs in clinical development, published in Current Opinion in Investigational Drugs, covered AOD-9604 among a field of candidate anti-obesity compounds being tested at the time ^[2]. It's a survey of the pipeline, not a verdict, but AOD-9604 didn't graduate out of that pipeline into an approved obesity drug, and there's no FDA-approved product for it. You can check that yourself in Drugs@FDA, the FDA's own database of approved drug products, where AOD-9604 does not appear as an approved obesity therapy ^[3]. A series of clinical trial registry summaries, published as 'Gateways to clinical trials' in Methods and Findings in Experimental and Clinical Pharmacology across 2003 and 2005, tracked AOD-9604 moving through development alongside many other investigational compounds of that era ^[4][5][6]. Registry listings confirm trials happened. They don't confirm the drug won. The honest summary: the fragment hypothesis (isolate the fat-metabolizing piece of hGH, skip the growth-promoting piece) is a reasonable scientific idea, and it's why AOD-9604 got tested at all. But reasonable hypotheses fail in human trials constantly, and this is one of them. Nobody has published a large, clean human trial showing AOD-9604 beats placebo for meaningful fat loss. If you're buying it expecting HGH-like results without the side effects, the trial record doesn't back that up. For a closer look at where AOD-9604 sits against other peptides people use for injury or performance, see the comparison section below.

is AOD-9604 legal to buy and does the FDA regulate it

AOD-9604 is not an FDA-approved drug, and it is not on the FDA's current list of bulk drug substances that compounding pharmacies may use under Section 503A of the Federal Food, Drug, and Cosmetic Act ^[7]. That list, maintained under 21 CFR 216.23 for 503A pharmacies and 21 CFR 216.24 for 503B outsourcing facilities, is the FDA's mechanism for deciding which unapproved bulk substances compounders can legally use in patient-specific prescriptions ^[8][9]. AOD-9604 doesn't appear on either list, meaning compounding it into a prescription product sits outside the FDA's approved compounding pathway. Pharmacy compounding itself is governed by 21 U.S.C. 353a, which sets conditions like a valid patient prescription and use of approved or listed bulk substances ^[10]. Products sold as 'research chemicals' or research-use-only try to sidestep this framework entirely by not making a therapeutic claim, but 21 CFR 201.128 defines a product's 'intended use' by how it's actually labeled, marketed, and understood to be used, more than by a disclaimer on the label ^[11]. Selling a peptide with dosing charts and fat-loss language while calling it research-only doesn't necessarily change its regulatory intended use. None of this means AOD-9604 is criminally illegal to possess in most circumstances. It means there's no FDA-approved product, no legitimate prescription pathway through the standard bulk substances list, and buyers are operating in a gray zone that depends heavily on sourcing and labeling.

will AOD-9604 show up on a drug test

If you're an athlete under a testing program, this question matters more than reconstitution technique ever will. A 2013 study in Drug Testing and Analysis specifically tested whether AOD-9604 interferes with or triggers the WADA hGH isoform immunoassay, the test anti-doping labs use to detect growth hormone doping, and found that AOD-9604 does not influence that assay ^[12]. That's a narrow, specific finding: it means AOD-9604 doesn't get flagged by the same isoform test used for full-length hGH. It does not mean AOD-9604 is undetectable or permitted. Separate detection science has moved fast. A 2014 paper in Expert Review of Proteomics covered analytical strategies for detecting peptide drugs and their analogs in sports doping controls generally ^[13], and a 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis covered analytical approaches for catching emerging, non-approved therapeutics in human doping controls ^[14]. A 2016 method in the Journal of Separation Science described a direct urine injection, liquid chromatography, and ion mobility mass spectrometry approach built specifically to screen for peptides under 2 kDa, a size range that includes fragments like AOD-9604 ^[15]. The short version: labs have built and published methods aimed at small peptides in this exact size class. Whether AOD-9604 specifically sits on any given sport's prohibited list is a separate question from whether it can be detected, and that's worth its own read. See our AOD-9604 and athletes drug testing guide for the fuller picture.

how does AOD-9604 compare to other peptides used for injury or performance

Two recent papers put AOD-9604 in context alongside other peptide therapies rather than treating it in isolation. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covered therapeutic peptides in orthopaedics broadly, including applications, challenges, and future directions across the peptide class ^[16]. A 2026 paper in Sports Medicine covered the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance ^[17]. The pattern across this literature is consistent: some peptides in this broader category have real approved uses and real trial support, while others, AOD-9604 among them, have mechanism-level plausibility and early-phase trial history but no approved indication and no convincing efficacy signal in humans for the use people actually want it for (fat loss). If your actual goal is FDA-approved, trial-backed fat loss, GLP-1 receptor agonists have a completely different evidence base, with large randomized trials and FDA approvals behind them. That's a different category of drug with a different risk and monitoring profile, but it's worth knowing the comparison exists before spending money on a compound whose own trial record didn't clear the placebo bar.

what does a provider-reviewed source actually add here

Reconstitution errors are avoidable with basic technique, but sourcing errors are harder to self-correct once you've already injected something. Vial content, actual peptide identity, sterility, and diluent quality vary a lot across sellers, and unregulated research-chemical vendors have no requirement to verify any of it. A provider-reviewed route, where a licensed pharmacy partner handles compounding and quality steps under a specific patient relationship, closes most of the sourcing risk that a random vial off a website carries. AOD-9604 Co reviews providers along this line and points readers toward the fulfilling pharmacy partner rather than anonymous international suppliers, precisely because the reconstitution technique in this article only matters if what's in the vial is what the label says it is. That said: sourcing quality doesn't manufacture efficacy. Even from a clean, well-reviewed source, you're still working with a compound whose human obesity trial data didn't clear placebo. Fix the sourcing risk if you're going to use it anyway, but don't let clean sourcing talk you into ignoring the trial record. If you haven't read the legal and regulatory background above, that's the section that explains why sourcing matters so much here.

what should you actually do with this information

If you're set on trying AOD-9604 anyway: use bacteriostatic water, add it slowly down the vial wall, never shake, refrigerate after mixing, and don't push past a few weeks of storage without fresh product. That part is genuinely simple and low-risk if you follow it. But go in with the right expectation. The trial record on AOD-9604 for fat loss is thin and it did not show a clear win over placebo in the human obesity studies that got published ^[1][2]. The fragment hypothesis, that you can isolate hGH's fat-burning piece and skip its growth effects, is a reasonable idea that justified running the trials. It just didn't pan out into an approved drug or a strong efficacy signal. If your priority is documented, FDA-approved efficacy for weight loss, look at drugs with actual large-trial data behind them rather than a fragment peptide whose own development pipeline stalled. If your priority is understanding AOD-9604 specifically before you decide, read our storage and shelf life guidance and our athlete drug testing guidance linked in this piece, and read the primary sources yourself rather than taking a seller's word for what the trials showed.

Frequently asked questions

What water do you use to reconstitute AOD-9604?

Bacteriostatic water, which contains 0.9% benzyl alcohol as a preservative, is standard for reconstituting AOD-9604 and most lyophilized peptides. Plain sterile water lacks a preservative and is meant for single-use only, not for a vial you'll draw from repeatedly over days or weeks.

Can you shake the vial to help AOD-9604 dissolve faster?

No. Shaking creates mechanical stress and foam that can damage peptide bonds. Let bacteriostatic water run gently down the inside wall of the vial, then swirl gently or let it sit undisturbed; most lyophilized peptide powders dissolve fully within a few minutes without agitation.

How much bacteriostatic water should I add to a 5 mg vial of AOD-9604?

There's no single correct volume; it depends on the concentration and injection volume you want. Adding 2 mL to a 5 mg vial gives roughly 2500 mcg/mL, while adding 5 mL gives roughly 1000 mcg/mL. Work out your target dose math before drawing anything into a syringe.

How long does reconstituted AOD-9604 last in the fridge?

Most compounded peptide solutions are handled as stable for a matter of weeks under refrigeration, though there's no large published stability study with an exact number specific to reconstituted AOD-9604. Keep it refrigerated, away from light, and don't stretch storage past a few weeks on a hopeful assumption.

Does AOD-9604 actually cause fat loss in humans?

The published human obesity trial record on AOD-9604 did not show weight loss results that clearly separated from placebo. A 2004 review covered its proposed metabolic mechanism, and a 2006 review placed it in the broader obesity-drug development pipeline, but it never reached an approved indication for fat loss.

Is AOD-9604 FDA-approved?

No. AOD-9604 does not appear in Drugs@FDA, the FDA's database of approved drug products, and it is not on the FDA's current 503A bulk drug substances list that compounding pharmacies may legally use under Section 503A of the FD&C Act.

Will AOD-9604 make me fail a drug test as an athlete?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay, the standard test for hGH doping. That's narrow: it doesn't mean AOD-9604 is undetectable by other methods or that it's permitted under any given sport's rules.

What's the difference between AOD-9604 and full HGH?

AOD-9604 is a synthetic fragment covering amino acids 176-191 of the human growth hormone molecule, the segment researchers proposed carries hGH's fat-metabolizing activity without its growth-promoting effects on bone and tissue. It is not full-length hGH and doesn't carry the same regulatory or clinical evidence base.

Can compounding pharmacies legally make AOD-9604 prescriptions?

AOD-9604 is not on the FDA's 503A bulk drug substances list (21 CFR 216.23) or the 503B list (21 CFR 216.24), which are the lists compounders use to determine which unapproved bulk substances they can legally compound into patient prescriptions. Its absence from those lists puts standard compounding of it outside the approved pathway.

How do I know if my AOD-9604 solution has gone bad?

A properly reconstituted solution should stay clear with no cloudiness, particles, or fibers. Any visible change, discoloration, or a solution that's been left unrefrigerated for an extended period should be discarded rather than injected, even if it looks mostly fine.

Is buying AOD-9604 online legal in the US?

It sits in a gray zone. It's not FDA-approved and isn't on the compounding bulk substances lists, and products labeled 'research use only' don't automatically escape FDA intended-use rules under 21 CFR 201.128 if they're marketed and dosed like a therapeutic product. It's not necessarily criminal to possess, but there's no clean legitimate prescription pathway for it.

What size needle do you use to inject reconstituted AOD-9604?

An insulin syringe with a 29 to 31 gauge needle is standard for peptide injections at the small volumes typically used. The same syringe is usually used both to add bacteriostatic water during reconstitution and to draw the final dose.

Sources

1. PubMed, Current Opinion in Investigational Drugs, 2004 (PMID 15134286): AOD-9604's proposed metabolic mechanism as an hGH fragment designed to retain fat-reducing activity
2. PubMed, Current Opinion in Investigational Drugs, 2006 (PMID 16625817): AOD-9604 was covered among obesity drugs in clinical development but did not reach approved status
3. FDA, Drugs@FDA approved drug products database: AOD-9604 does not appear as an FDA-approved obesity therapy
4. PubMed, Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14685303): Clinical trial registry tracking of AOD-9604's development alongside other investigational compounds
5. PubMed, Methods and Findings in Experimental and Clinical Pharmacology, 2003 (PMID 14571286): Additional clinical trial gateway listing covering AOD-9604 development period
6. PubMed, Methods and Findings in Experimental and Clinical Pharmacology, 2005 (PMID 15834452): Continued clinical trial registry tracking of AOD-9604 through 2005
7. FDA, bulk drug substances used in compounding under section 503A: AOD-9604 is not on the FDA's current list of bulk substances permitted for 503A compounding
8. eCFR, 21 CFR 216.23, the 503A Bulks List: 21 CFR 216.23 establishes the bulk drug substances list for 503A compounding pharmacies
9. eCFR, 21 CFR 216.24, the 503B Bulks List: 21 CFR 216.24 establishes the bulk drug substances list for 503B outsourcing facilities
10. Cornell Law School Legal Information Institute, 21 U.S.C. 353a: Federal pharmacy compounding requires a valid patient prescription and use of approved or listed bulk substances
11. eCFR, 21 CFR 201.128, meaning of intended uses: A product's regulatory intended use is defined by labeling and marketing context, not disclaimers alone
12. PubMed, Drug Testing and Analysis, 2013 (PMID 24124033): AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing
13. PubMed, Expert Review of Proteomics, 2014 (PMID 25382550): Analytical strategies exist for detecting peptide drugs and analogs in sports doping controls
14. PubMed, Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): Analytical approaches have been developed for detecting emerging non-approved therapeutics in doping controls
15. PubMed, Journal of Separation Science, 2016 (PMID 26578461): A direct urine injection LC-ion mobility mass spectrometry method was developed to screen peptides under 2 kDa
16. PubMed, JAAOS Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics covering applications, challenges, and future directions
17. PubMed, Sports Medicine, 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance